This title is printed to order. This book may have been self-published. If so, we cannot guarantee the quality of the content. In the main most books will have gone through the editing process however some may not. We therefore suggest that you be aware of this before ordering this book. If in doubt check either the author or publisher’s details as we are unable to accept any returns unless they are faulty. Please contact us if you have any questions.
This Reprint of the IJMS Special Issue "Circulating Non-Coding RNAs as Diagnostic and Prognostic Markers of Human Diseases" presents eight original research papers and five reviews that advance our diagnostic, prognostic, and mechanistic understanding of circulating non-coding RNAs (c-ncRNAs). The collection emphasizes the remarkable stability of c-ncRNAs in biofluids such as blood and urine, their tissue- and disease-specific expression profiles, and their growing promise in non-invasive liquid biopsy for precision medicine, spanning early detection, risk assessment, and therapeutic monitoring. Featured studies explore early lung cancer prediction in COPD via miR-206 and miR-1246; risk stratification in atrial fibrillation using miR-411-5p; the differentiation of coronary artery aneurysmal disease through miR-451a and miR-328-3p; the staging of mycosis fungoides by plasma miR-146a and miR-155; and asthma phenotyping associated with hsa-miR-26a-1-3p and hsa-miR-376a-3p. Additional research investigates NAFLD diagnostics using serum miRNA ratios and provides mechanistic insight into muscle development via circTTN. The reviews synthesize advances on c-miRNAs in osteoarthritis, miRNA and exosomal miRNA dysregulation in cholesteatoma, therapeutic biomarkers in asthma, and post-SARS-CoV-2 cardiovascular alterations, highlighting broad clinical relevance across oncologic, cardiovascular, metabolic, and inflammatory disorders. Collectively, these contributions underscore methodological progress toward standardization and position c-ncRNAs at the forefront of minimally invasive diagnostics and personalized therapy.
